Sam Reich

CEO SAB BIO, 🇺🇸✡️🇮🇱

[SAB BIO @SABBantibody]

How can preserving the insulin-producing beta cells that remain at type 1 diabetes (T1D) diagnosis change the future of T1D care?

Find out on the Reclaim Your Rise podcast! SAB BIO CEO @SamuelJReich1 joins host Lauren Bongiorno to discuss the science behind SAB-142, an investigational therapy being studied for its potential to preserve beta-cell function in people newly diagnosed with Stage 3 T1D.

Sam shares why protecting remaining beta cells matters, how SAB-142 is being studied in the SAFEGUARD trial, and how continued research could inform future approaches to T1D care.

Listen to the conversation: https://t.co/HZGoRUi7wH

Learn more about the SAFEGUARD Study: https://t.co/ftSibtzy3H

#Type1Diabetes #T1D #ClinicalResearch #DiabetesResearch

[SAB BIO @SABBantibody]

In a recent episode of Integrated Diabetes Services' Think Like a Pancreas: The Podcast, SAB BIO CEO @SamuelJReich1 joined host Gary Scheiner, MS, CDCES to discuss the growing focus on disease-modifying therapies in type 1 diabetes (T1D) and the importance of continued clinical research to advance new treatment approaches.

The conversation explores the science behind SAB-142, an investigational therapy designed to help preserve insulin-producing beta cells, as well as the registrational SAFEGUARD study evaluating SAB-142 in people newly diagnosed with T1D to see if it can prevent disease progression.

We're grateful for the opportunity to be part of the conversation and share more about the research underway to address the underlying autoimmune drivers of T1D.

Listen to the episode: https://t.co/c339vKwekg

#Type1Diabetes #T1D #DiabetesResearch #SABBIO #SAFEGUARDStudy

[SAB BIO @SABBantibody]

SAB BIO is in Milan for #EASD2026!

We’re proud to join the global diabetes community to share research from our SAB-142 program and engage in important conversations about the future of type 1 diabetes research.

Today, Chief Medical Officer Alexandra Kropotova, M.D., MBA, will participate in the INNODIA Symposium on Type 1 Diabetes Therapies, followed by additional SAB BIO presentations on September 30 highlighting Phase 1 findings from SAB-142.

We look forward to connecting with researchers, clinicians and others working to advance the science of T1D throughout the week.

#Type1Diabetes #T1D #DiabetesResearch #EASD

[SAB BIO @SABBantibody]

We’re looking forward to joining the type 1 diabetes community at the Touched by Type 1 Annual Conference tomorrow, 9/26 in Orlando.

The event brings together people living with T1D, families, caregivers and experts for a day of education, connection and community.

If you’re attending, stop by booth 2 to meet the SAB BIO team and learn more about our work to advance a new approach to treating type 1 diabetes.

We hope to see you there!

#SABBIO #Type1Diabetes #T1D #TouchedByType1

[SAB BIO @SABBantibody]

We’re heading to Milan for #EASD2026.

SAB BIO will present data on SAB-142, our potentially disease-modifying, redosable immunotherapy in clinical development for Stage 3 type 1 diabetes, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), September 28–October 2.

Across multiple presentations, our team will share Phase 1 findings exploring SAB-142’s mechanism of action, potential for safe redosing and early evidence of C-peptide preservation.

Learn more about our upcoming presentations: https://t.co/qgXxrKEq0n

#Type1Diabetes #T1D #DiabetesResearch #EASD

[SAB BIO @SABBantibody]

Our CEO, @SamuelJReich1, recently joined the Empowered Patient Podcast to discuss the evolving type 1 diabetes treatment landscape, the growing potential of disease-modifying therapies, and SAB BIO's work advancing innovative approaches designed to address the underlying drivers of disease.

During the conversation, he also shared insights into our investigational candidate, SAB-142, and the ongoing Phase 2b SAFEGUARD clinical trial.

Listen to the full episode here: https://t.co/nvStKNv8V1

[SAB BIO @SABBantibody]

We will report our Q2 2026 financial results on Thursday, August 6, 2026, and host an earnings webcast at 8:30 a.m. ET to discuss the results and provide business updates.

📅 August 6, 2026 at 8:30 AM ET
🔗 Register and join us for the webcast here: https://t.co/Mcns8hGVIl

View the press release with conference call details here: https://t.co/7joE1a0GYM

#Earnings #Biotech $SABS

[Sam Reich @SamuelJReich1]

At SAB BIO, our commitment to people living with type 1 diabetes (T1D) is strengthened by team members who have a personal connection to the disease.
Carl, our IT Manager, has lived with T1D for more than 20 years. His story is a powerful reminder of the daily realities people face and why we're committed to advancing new treatment options.
I’m proud to share Carl’s story and the hope that keeps him looking toward the future. #T1D #PatientStories #Type1Diabetes

[SAB BIO @SABBantibody]

For Carl, IT Manager at SAB BIO, type 1 diabetes (T1D) is something he's lived with for more than two decades. Every day brings decisions, routines, and challenges that many people never see. That experience is what makes his work so personal.

Across our organization, many team members are driven by a personal connection to T1D. This shared perspective strengthens our commitment to advancing innovative research. Carl's story is a reminder of why the work matters and who we're working for.

Hear from Carl as he shares what it's really like to live with T1D and what gives him hope for the future.

#LifeAtSAB #Type1Diabetes #T1D

[SAB BIO @SABBantibody]

For Carl, IT Manager at SAB BIO, type 1 diabetes (T1D) is something he's lived with for more than two decades. Every day brings decisions, routines, and challenges that many people never see. That experience is what makes his work so personal.

Across our organization, many team members are driven by a personal connection to T1D. This shared perspective strengthens our commitment to advancing innovative research. Carl's story is a reminder of why the work matters and who we're working for.

Hear from Carl as he shares what it's really like to live with T1D and what gives him hope for the future.

#LifeAtSAB #Type1Diabetes #T1D

[Sam Reich @SamuelJReich1]

I am pleased to see SAB BIO featured in BioSpace today. The shift from insulin-only management to disease modification represents a fundamental change in what's possible for T1D patients. Our registrational Phase 2b SAFEGUARD trial is underway. The opportunity to change the course of a T1D diagnosis is what makes this work so meaningful. Read the full article: https://t.co/u7bXiVjYFi

#Type1Diabetes #ClinicalDevelopment

[SAB BIO @SABBantibody]

A clinical study is now enrolling people with newly diagnosed type 1 diabetes (T1D). Find out more about the SAFEGUARD clinical study and see if you are eligible to participate: https://t.co/zq1n0k6p2l

[Sam Reich @SamuelJReich1]

A clinical study is now enrolling people with newly diagnosed type 1 diabetes (T1D). Find out more about the SAFEGUARD clinical study and see if you are eligible to participate. Learn more at: 1-844-763-1890 or [email protected].

#TheSAFEGUARDstudy #Type1diabetes #T1D #ClinicalResearch

[Sam Reich @SamuelJReich1]

I am proud to share that @BreakthroughT1D has awarded a grant to Dr. @HallerMichael to support PRISE-hATG, a study evaluating SAB-142 in people with Stage 3 #T1D beyond 100 days to 2 years after diagnosis. Expanding treatment options for those living with T1D remains our mission, and this study represents an important step forward alongside our ongoing SAFEGUARD Phase 2b trial. View announcement: Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes | SAB Biotherapeutics

[Sam Reich @SamuelJReich1]

Great discussion with @staceysimms  and Dr. Michael Haller on Diabetes Connections—we cover SAB-142 and our ongoing SAFEGUARD study in stage 3 type 1 diabetes. Appreciate the conversation and ongoing support for the T1D community. Listen here: https://t.co/1D1sAL0s79
#Type1Diabetes #T1D #DiabetesResearch

[Michael Haller, M.D. @HallerMichael]

Type 1 diabetes (T1D) knows no boundaries—but access to screening and post-diagnostic care does. [1,2] Adolescents and young adults in rural communities are at greater risk of delayed diagnosis of T1D, often presenting with life-threatening diabetic ketoacidosis (DKA). [2] Research shows that living far from specialized care and lacking access to technologies can lead to worse health outcomes. [2] And these challenges don’t stop there—they’re compounded for those facing language barriers or financial hardships. [1,3]

Research published in 2023 in the Journal of Pediatric Health Care found that delayed referral and diagnosis in rural areas negatively affected T1D management, creating health inequities. [2] This delay often stems from limited access to specialized care or awareness of T1D symptoms among primary care providers. [2]

And a 2023 study published in Frontiers in Clinical Diabetes and Healthcare found that individuals with limited English language proficiency had a significantly higher HbA1c than those not needing an interpreter. [1] Language barriers and rural residence can correlate to lower health literacy, poorer glycemic control, and delayed interventions for T1D. [1] And it’s a double whammy when someone faces the simultaneous challenge of a language barrier and living in a rural setting. [4]

We can do more, and we must do more, to bend these trends by advocating for vigilance in T1D, screening for those with potential risk AND advocating for clear, plain-language educational information and broader access to specialized care for those impacted.

I’ve been engaged by Sanofi to highlight the importance of taking action to screen for T1D, what we can do to support patients who may be at risk, and when to advocate for them. Check out https://t.co/TpM4SwtSty [https://t.co/YVwZBZyGWg] for more information you can share with your patients, and tools in multiple languages!! Together, we can transform how T1D is diagnosed. Let’s make screening the new standard of care!

#Sponsored #Sanofi_Partner #T1D #Type1Diabetes #screenforT1D #PaidPartner #HealthEquity #Type1Diabetes #ScreenForAll #EarlyDiagnosisMatters #InclusiveHealthcare #DEIinMedicine #T1DCommunity #EndHealthDisparities

References
1. Idkowiak J, et al. Front Clin Diabetes Healthc. 2023;4:1228820.
2. Jewell VD, et al. J Pediatr Health Care. 2023;37(1):48-55.
3. Lin MH, et al. Diabetes Technol Ther. 2013;15(11):929-934.
4. Detz A, et al. J Gen Intern Med. 2014;29(12):1650-1656.

[Sam Reich @SamuelJReich1]

I was surprised to see this nice write up in LinkedIn this morning
https://t.co/gjp53aJkuJ

[Project Blue November @PBlueNovember]

#T1D #Type1Diabetes #diabetes #dontmakeme

[Sam Reich @SamuelJReich1]

@zach_yadegari Zach You made the right choice! From an Ivy league grad whose daughter is a happy student at the U- !

[Project Blue November @PBlueNovember]

#T1D #Type1Diabetes #projectbluenovember

[SAB BIO @SABBantibody]

COMING UP FEB 12: $SABS CEO will be joining Oppenheimer Health Conf on Feb 12 at 10:00am EST fireside. Webcast Link: https://t.co/yNcQyuWq93